# Filing Detail

Form 8-K - Current report:
SEC Accession No. 0001104659-19-006667
Filing Date
2019-02-08
Accepted
2019-02-08 11:49:32
Documents
7
Period of Report
2019-02-08
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 8-K | a19-4170_18k.htm | 8-K | 32994
2 | EX-3.1 | a19-4170_1ex3d1.htm | EX-3.1 | 13642
3 | EX-4.1 | a19-4170_1ex4d1.htm | EX-4.1 | 9180
4 | EX-99.1 | a19-4170_1ex99d1.htm | EX-99.1 | 11704
5 | GRAPHIC | g41701kwi001.gif | GRAPHIC | 598076
6 | GRAPHIC | g41701kxi001.gif | GRAPHIC | 105587
7 | GRAPHIC | g41701mmi001.jpg | GRAPHIC | 5342
| Complete submission text file | 0001104659-19-006667.txt |  | 1045525

Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Filer) CIK: 0000744218 (see all company filings)

EIN.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-15006 | Film No.: 19578678
SIC: 2835 In Vitro & In Vivo Diagnostic Substances